Skip to main content

20th International Myeloma Workshop Main banner

Treatment of Newly Diagnosed Myeloma - Non-Transplant Eligible

Treatment of Newly Diagnosed Myeloma - Non-Transplant Eligible

Type here to filter the list

P-105: Multiple Myeloma Therapy in Tawam Hospital. First Report from United Arab Emirates
P-106: Clinical outcomes of older patients aged 80 and over with newly diagnosed multiple myeloma
P-107: The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings
P-108: Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. CARINAE Study.
P-109: Carfilzomib-Lenalidomide-Dexamethasone Vs. Lenalidomide-Dexamethasone in Non-Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: The EMN20 Trial
P-110: Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: Final overall survival analysis from the TOURMALINE-MM4 study
P-111: Overall survival trends in young (<55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system
P-112: Determining the impact of multimorbidity in older patients initiating treatment for newly-diagnosed multiple myeloma using artificial intelligence/machine learning methods
P-113: Clinical Consensus on First-Line (1L) Treatments for Transplant-Ineligible (TIE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Delphi Panel of US Hematologists and Oncologists
P-114: In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study
P-115: Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Chart Review Study
P-116: The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)
P-117: A prognostic score based on age, eGFR (CKD-EPI), performance status and ultra-high-risk disease outperforms R2-ISS for elderly myeloma patients: An analysis of the Greek Myeloma Study Group Registry
P-118: Machine learning assisted risk stratification of newly diagnosed multiple myeloma with respect to the VRd treatment
P-119: The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy
P-120: Impact of exclusion from clinical trials in non-candidate transplant patients with newly diagnosed multiple myeloma
P-121: Real World Outcomes of Undocumented Multiple Myeloma Patients: A Safety Net Hospital Experience
P-122: Ocular Adverse Events and Functional Impact in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients Treated with Belantamab Mafodotin, Lenalidomide and Dexamethasone in BelaRd Trial
P-123: Safety and Clinical Activity of Belantamab Mafodotin plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2 BelaRd study
P-124: Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty
P-125: Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in China